Recommendations for clinical trial development in follicular lymphoma

Kami Maddocks; Paul M. Barr; Bruce D. Cheson; Richard F. Little; Lawrence Baizer; Brad S. Kahl; John P. Leonard; Nathan Fowler; Leo I. Gordon; Brian K. Link; Jonathan W. Friedberg; Stephen M. Ansell

doi:10.1093/jnci/djw255

Recommendations for clinical trial development in follicular lymphoma

Kami Maddocks, Paul M. Barr, Bruce D. Cheson, Richard F. Little, Lawrence Baizer, Brad S. Kahl, John P. Leonard, Nathan Fowler, Leo I. Gordon, Brian K. Link, Jonathan W. Friedberg, Stephen M. Ansell

Hematology

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non- Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.

Original language	English (US)
Journal	Journal of the National Cancer Institute
Volume	109
Issue number	3
DOIs	https://doi.org/10.1093/jnci/djw255
State	Published - Mar 2017

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1093/jnci/djw255

Cite this

@article{bfc00d2b80054621beeb9893ed92d30d,

title = "Recommendations for clinical trial development in follicular lymphoma",

abstract = "Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non- Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.",

author = "Kami Maddocks and Barr, {Paul M.} and Cheson, {Bruce D.} and Little, {Richard F.} and Lawrence Baizer and Kahl, {Brad S.} and Leonard, {John P.} and Nathan Fowler and Gordon, {Leo I.} and Link, {Brian K.} and Friedberg, {Jonathan W.} and Ansell, {Stephen M.}",

note = "Publisher Copyright: {\textcopyright} The Author 2017.",

year = "2017",

month = mar,

doi = "10.1093/jnci/djw255",

language = "English (US)",

volume = "109",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Recommendations for clinical trial development in follicular lymphoma

AU - Maddocks, Kami

AU - Barr, Paul M.

AU - Cheson, Bruce D.

AU - Little, Richard F.

AU - Baizer, Lawrence

AU - Kahl, Brad S.

AU - Leonard, John P.

AU - Fowler, Nathan

AU - Gordon, Leo I.

AU - Link, Brian K.

AU - Friedberg, Jonathan W.

AU - Ansell, Stephen M.

PY - 2017/3

Y1 - 2017/3

N2 - Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non- Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.

AB - Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non- Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.

UR - http://www.scopus.com/inward/record.url?scp=85016062382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016062382&partnerID=8YFLogxK

U2 - 10.1093/jnci/djw255

DO - 10.1093/jnci/djw255

M3 - Review article

C2 - 28040699

AN - SCOPUS:85016062382

SN - 0027-8874

VL - 109

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 3

ER -

Recommendations for clinical trial development in follicular lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this